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Propositions 
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Yang Yu 
1. In individual subjects, intrasubject variability plays a decisive role in difference in 
drug exposure of generic and the brand-name drug. The difference in drug 
exposure of generic and the brand-name drug is comparable with it of two 
occasions of generic or the brand-name drug.  
2. Post-marketing variations in drug quality aspects do not seem to have impact on 
the demonstrated bioequivalence of a generic drug with the brand-name drug 
at the registration.  
3. The current requirement for registration of a generic drug does not hamper 
interchangeability of generic and generic drugs.   
4. The methods applied in the studies in the dissertation, such as inter-study 
comparisons and the model to evaluate cumulative impact of quality variations, 
can be used for further investigation. 
5. Demonstration of bioequivalence between generic and the brand-name drug in 
healthy subjects can be extrapolated to patient populations.  
6. It is difficult  for biosimilar drugs to prove therapeutic equivalence with the 
brand-name drug via pharmacokinetic bioequivalence study. Investigation for 
the potential criteria of using pharmacodynamics parameters for demonstration 
of biosimilar is demand.  
7. Switching to generic drugs from the brand-name drug is considered to not 
change the treatment in terms of effectiveness and safety. It however should 
not be interpreted as a support for switching the drugs in patients.   
8. As legislation for ensuring bioequivalence between a generic and other generic 
drugs is not available, it is useful to repeat the investigation for generic-generic 
interchangeability after a couple of years when more and more generic drugs 
are registered.  
